The BOPA-PRUK research award

The BOPA-PRUK research award

This award provides pharmacy professionals who are new to research with the extra incentive to get their research career started.

Pharmacy Research UK (PRUK) and the British Oncology Pharmacy Association (BOPA) have collaborated together for 6 years to provide this opportunity to oncology and haematology pharmacy colleagues.  Multiple people have already benefited from this generous award.

This year, the award is worth £20,000. This allows us to offer the whole amount to a single person or to break the award down to offer more people smaller amounts of a minimum of £5,000. The funding can be used to partly or fully fund a research project.

Any member of the pharmacy team can apply. Projects must be related to the provision of oncology or haematology pharmacy services directly impacting patient care and benefit.

For further information please refer to the PRUK website. We recommend you read through all the material contained within the PRUK website before starting your application.

PRUK offer a mentoring scheme available to pharmacy professionals who wish to seek guidance and support for developing their research skills. If you think you could benefit from this please refer to the PRUK webpage.

Latest News

By UK SACT Board Representatives - Joseph Williams and Netty Cracknell on 16th September 2025

Proposals for the reshaping of cancer services in England: funding for innovative cancer treatments

The Royal College of Radiologists (RCR) and the Society of Radiographers (SoR) have published a short document that expands on previous proposals for improving funding arrangements to enable equitable access…

Read article
By BOPA Exec Committee on 15th September 2025

Invitation to visit the BOPA stand at the BOPA Conference in Belfast

Hello All As an Executive Committee we are looking forward to meeting those of you who are signed up to come to the conference in Belfast next month. The BOPA…

Read article
By BOPA Research subcommittee on 14th September 2025

Survey: Fertility and the use of Immune Checkpoint Inhibitor Therapy (Survey from Royal Marsden Hospital)

Immune checkpoint inhibitors, such as atezolizumab, nivolumab and pembrolizumab have transformed the treatment landscape for many cancers. Cancers such as melanoma and Lynch-syndrome related tumours necessitating immune checkpoint inhibitors are…

Read article
By Clayton Wong on 8th September 2025

British Oncology Pharmacy Association (BOPA) invites you to Clinical Pharmacy Congress North 2025

British Oncology Pharmacy Association (BOPA) invites you to Clinical Pharmacy Congress North 21-22 November 2025 | Manchester Central Confirm your free delegate place *free places are only available for registered healthcare…

Read article